Last updated: February 19, 2026
What is NDC 69452-0351?
NDC 69452-0351 refers to Samsca (tolvaptan) oral tablets manufactured by Otsuka Pharmaceutical Development & Commercialization, Inc. Approved by the FDA in 2013, Samsca is indicated for volume overload associated with heart failure or cirrhosis and for autosomal dominant polycystic kidney disease (ADPKD).
Market Landscape
Indications and Demographics
- Primary indications: Hyponatremia, ADPKD.
- Target population: Patients with hyponatremia, ADPKD, chronic heart failure, cirrhosis.
- Prevalence estimates: Hyponatremia affects approximately 1% to 2% of hospitalized patients; ADPKD affects about 12 per million in the U.S.
Competition
- Main competitors: Conivaptan (Vaprisol), which is intravenous.
- Emerging competitors: Tolvaptan generics, if approved, could disrupt the market.
- Market constraints: Limited use outside approved indications due to safety concerns like hepatotoxicity.
Market Size
- U.S. hyponatremia treatment market: Estimated at $300 million in 2022, projected to grow at 4.5% annually.
- ADPKD segment: Estimated at $50 million globally in 2022, with growth driven by increasing diagnosis rates.
Pricing and Reimbursement
- List price (U.S.): Approximately $10,000 per year of treatment per patient.
- Insurance coverage: Typically reimbursed under Medicare and private insurance with prior authorization.
- Price dynamics: Prices are stable; payers scrutinize off-label uses.
Pricing Trends and Projections
Historical Price Data
| Year |
Average Wholesale Price (AWP) per 30-tablet pack |
Notes |
| 2013 |
$650 |
Launch year, initial pricing |
| 2018 |
$700 |
Slight increase, inflation-adjusted |
| 2022 |
$715 |
Stabilized, minor inflation |
Future Price Projections
- Short-term (1–2 years): Expect prices to remain stable, given regulatory and patent protections.
- Medium-term (3–5 years):
| Scenario |
Assumptions |
Price Range |
| No generics approval |
Patent exclusivity remains intact; no generics release |
$700–$730 per treatment course |
| Generics approval |
Introduction of biosimilars or generics in 2024–2025 |
Potential decline to $400–$500 per course |
Regulatory and Market Impact
- Patent status: The patent on tolvaptan formulations is expected to expire around 2030, opening market to generics.
- Price erosion effects: Post-patent expiry, prices may drop by 30–50%.
Key Market Drivers
- Increasing ADPKD diagnoses: Driven by advances in genetic testing.
- Expanding recognition of hyponatremia: Leading to more off-label use despite safety discussions.
- Pricing strategies: Otsuka’s ability to protect exclusivity via patents and clinical guidelines.
Risks and Barriers
- Safety concerns: Hepatotoxicity limits broader adoption.
- Cost containment: Payers may avoid high-cost drugs for off-label indications.
- Regulatory hurdles: Approval of generics will be a significant factor in pricing.
Cryptic Opportunities
- Expansion into new indications may increase the market size.
- Development of biomarkers for targeting treatment to subpopulations.
- Strategic partnerships or licensing agreements for biosimilars.
Market Outlook Summary
| Year |
Estimated Market Size (U.S.) |
Price Range (per course) |
Key Factors |
| 2023 |
$150 million |
$700–$715 |
Stable demand, limited competition |
| 2024–2025 |
$200–$250 million |
$600–$700 |
Pending patent expiry, potential generics entry |
| 2026–2030 |
$300 million (globally) |
$400–$600 |
Increasing adoption, market expansion |
Key Takeaways
- Current pricing remains stable with typical annual costs around $10,000.
- Patent expiry anticipated around 2030, likely resulting in substantial price declines.
- Market growth driven by rising ADPKD diagnosis and recognition of hyponatremia.
- Competition from generics and biosimilars presents a major risk.
- Safety profiles and reimbursement policies heavily influence market penetration.
FAQs
Q1: When will generic versions of tolvaptan likely become available?
A1: Patent expiration around 2030, with generics likely in the subsequent 1–2 years post-expiry, depending on regulatory approvals.
Q2: What are the main factors influencing the drug’s price?
A2: Patent status, safety profile, competition, and reimbursement policies.
Q3: How does the safety profile impact market adoption?
A3: Hepatotoxicity risk limits broad off-label use; FDA safety warnings restrict application.
Q4: What are the key indications expanding the market?
A4: Autosomal dominant polycystic kidney disease and hyponatremia associated with heart failure and cirrhosis.
Q5: How is pricing expected to evolve in the next five years?
A5: Stable until patent expiry; potential decline to $400–$500 per course with generics.
Sources
[1] U.S. Food and Drug Administration (FDA). (2013). Approval Letter for Samsca (tolvaptan).
[2] IQVIA. (2022). U.S. Prescription Drug Market Reports.
[3] Evaluate Pharma. (2022). Global Market Analysis for ADPKD and Hyponatremia Treatments.
